The Patent Cooperation Treaty (PCT) enables applicants to file a single standardized patent application, and have that application treated as a regular national patent application in 153 Member Countries to the PCT.
The PCT process is advantageous when there is a clear global need and likely markets exist around the world, such as with pharmaceuticals, anything involving standard essential patents (SEPs), and for universities with important, paradigm shifting innovations. But as the U.S. patent system becomes less attractive for many innovators, the PCT process is becoming more relevant for a variety of reasons.
On Tuesday, March 2, 2021, at 12pm EST, please join Gene Quinn, patent attorney and founder of IPWatchdog.com, twice named one of the most influential people in the IP world, for a one-hour discussion on the nuances of the PCT. Joining Gene for the hour will be patent attorney and PCT expert John White, who is President and CEO of the PCT Learning Center.
In addition to taking questions from the audience, we will address:
- When is the PCT the best choice;
- Filing an International Application under the PCT;
- The International Stage;
- Entry into the U.S. National Stage.